Mankind Pharma Share Price
Sector:
2538.00 -22.20 (-0.87%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
2530.00
Today’s High
2580.90
52 Week Low
1910.10
52 Week High
3050.00
2549.20 -15.00 (-0.58%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
2525.40
Today’s High
2587.00
52 Week Low
1901.05
52 Week High
3054.80
Key Metrics
- Market Cap (In Cr) 104829.12
- Beta -
- Div. Yield (%) 0
- P/B 10.97
- TTM P/E 56.58
- Peg Ratio 3.43
- Sector P/E 24.5
- Open Price 2566.15
- Prev Close 2560.2
Mankind Pharma Analysis
Price Analysis
-
1 Week2.57%
-
3 Months9.31%
-
6 Month-1.3%
-
YTD-10.98%
-
1 Year21.43%
Risk Meter
- 36% Low risk
- 36% Moderate risk
- 36% Balanced Risk
- 36% High risk
- 36% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 5
- 4
- 4
- 5
- Buy
- 5
- 5
- 5
- 5
- Hold
- 2
- 2
- 2
- 2
- Sell
- 2
- 2
- 2
- 2
- Strong Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Total
- 14
- 13
- 13
- 14
Mankind Pharma News
Chalet Hotels revenue jumps 21.3% in FY25 but profit drops on higher expenses
2 min read . 12 May 2025Vahdam Teas raises ₹25 crore from Sidbi Venture to boost global expansion
2 min read . 26 Mar 2025Mankind Pharma Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 10334.77
- Selling/ General/ Admin Expenses Total
- 3306.91
- Depreciation/ Amortization
- 398.2
- Other Operating Expenses Total
- 1084.43
- Total Operating Expense
- 8195.7
- Operating Income
- 2139.08
- Net Income Before Taxes
- 2399.36
- Net Income
- 1912.9
- Diluted Normalized EPS
- 47.66
- Period
- 2024
- Total Assets
- 11963.25
- Total Liabilities
- 2600.17
- Total Equity
- 9363.09
- Tangible Book Valueper Share Common Eq
- 191.72
- Period
- 2024
- Cashfrom Operating Activities
- 2152.45
- Cashfrom Investing Activities
- -2081.69
- Cashfrom Financing Activities
- 5.27
- Net Changein Cash
- 77.19
- Period
- 2023
- Total Revenue
- 8749.43
- Selling/ General/ Admin Expenses Total
- 3763.95
- Depreciation/ Amortization
- 325.86
- Total Operating Expense
- 7174.72
- Operating Income
- 1574.72
- Net Income Before Taxes
- 1671.24
- Net Income
- 1281.86
- Diluted Normalized EPS
- 32.06
- Period
- 2023
- Total Assets
- 9715.45
- Total Liabilities
- 2280.23
- Total Equity
- 7435.22
- Tangible Book Valueper Share Common Eq
- 141.21
- Period
- 2023
- Cashfrom Operating Activities
- 1813.3
- Cashfrom Investing Activities
- -1054.13
- Cashfrom Financing Activities
- -739.73
- Net Changein Cash
- 21.76
- Period
- 2022
- Total Revenue
- 7781.56
- Selling/ General/ Admin Expenses Total
- 3209.56
- Depreciation/ Amortization
- 166.56
- Total Operating Expense
- 5929.56
- Operating Income
- 1851.99
- Net Income Before Taxes
- 1974.6
- Net Income
- 1433.48
- Diluted Normalized EPS
- 35.36
- Period
- 2022
- Total Assets
- 9147.74
- Total Liabilities
- 2992.51
- Total Equity
- 6155.23
- Tangible Book Valueper Share Common Eq
- 106.36
- Period
- 2022
- Cashfrom Operating Activities
- 919.78
- Cashfrom Investing Activities
- -1369.14
- Cashfrom Financing Activities
- 604.62
- Net Changein Cash
- 155.73
- Period
- 2021
- Total Revenue
- 6214.43
- Selling/ General/ Admin Expenses Total
- 2583.6
- Depreciation/ Amortization
- 118.92
- Other Operating Expenses Total
- 50.58
- Total Operating Expense
- 4682.26
- Operating Income
- 1532.18
- Net Income Before Taxes
- 1691.61
- Net Income
- 1265.43
- Diluted Normalized EPS
- 31.98
- Period
- 2021
- Total Assets
- 6372.63
- Total Liabilities
- 1650.63
- Total Equity
- 4722
- Tangible Book Valueper Share Common Eq
- 116.9
- Period
- 2021
- Cashfrom Operating Activities
- 1137.24
- Cashfrom Investing Activities
- -1222.21
- Cashfrom Financing Activities
- -7.81
- Net Changein Cash
- -92.4
- Period
- 2020
- Total Revenue
- 5865.23
- Selling/ General/ Admin Expenses Total
- 2294.37
- Depreciation/ Amortization
- 99.05
- Other Operating Expenses Total
- 40.14
- Total Operating Expense
- 4518.47
- Operating Income
- 1346.77
- Net Income Before Taxes
- 1437.74
- Net Income
- 1030.43
- Diluted Normalized EPS
- 27.27
- Period
- 2020
- Total Assets
- 5073.29
- Total Liabilities
- 1587.98
- Total Equity
- 3485.31
- Tangible Book Valueper Share Common Eq
- 85.85
- Period
- 2020
- Cashfrom Operating Activities
- 1069.71
- Cashfrom Investing Activities
- -439.16
- Cashfrom Financing Activities
- -530.74
- Net Changein Cash
- 103.42
- Period
- 2024-12-31
- Total Revenue
- 3230
- Selling/ General/ Admin Expenses Total
- 709.71
- Depreciation/ Amortization
- 192.3
- Other Operating Expenses Total
- 755.27
- Total Operating Expense
- 2592.5
- Operating Income
- 637.5
- Net Income Before Taxes
- 497.33
- Net Income
- 380.23
- Diluted Normalized EPS
- 9.44
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 3076.51
- Selling/ General/ Admin Expenses Total
- 646.43
- Depreciation/ Amortization
- 105.62
- Other Operating Expenses Total
- 705.15
- Total Operating Expense
- 2332.09
- Operating Income
- 744.42
- Net Income Before Taxes
- 849.32
- Net Income
- 653.47
- Diluted Normalized EPS
- 16.28
- Period
- 2024-09-30
- Total Assets
- 13982.25
- Total Liabilities
- 3417.49
- Total Equity
- 10564.76
- Tangible Book Valueper Share Common Eq
- 222.76
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 1139.33
- Cashfrom Investing Activities
- -1035.42
- Cashfrom Financing Activities
- 240.51
- Net Changein Cash
- 344.62
- Period
- 2024-06-30
- Total Revenue
- 2893.42
- Selling/ General/ Admin Expenses Total
- 633.78
- Depreciation/ Amortization
- 107.74
- Other Operating Expenses Total
- 765.35
- Total Operating Expense
- 2319.4
- Operating Income
- 574.02
- Net Income Before Taxes
- 667.62
- Net Income
- 536.49
- Diluted Normalized EPS
- 13.37
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 2441.1
- Selling/ General/ Admin Expenses Total
- 599.89
- Depreciation/ Amortization
- 104.69
- Other Operating Expenses Total
- 512.81
- Total Operating Expense
- 1954.68
- Operating Income
- 486.42
- Net Income Before Taxes
- 571.58
- Net Income
- 471.24
- Diluted Normalized EPS
- 11.74
- Period
- 2024-03-31
- Total Assets
- 11963.25
- Total Liabilities
- 2600.17
- Total Equity
- 9363.09
- Tangible Book Valueper Share Common Eq
- 191.72
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 2152.45
- Cashfrom Investing Activities
- -2081.69
- Cashfrom Financing Activities
- 5.27
- Net Changein Cash
- 77.19
- Period
- 2023-12-31
- Total Revenue
- 2606.96
- Selling/ General/ Admin Expenses Total
- 568.35
- Depreciation/ Amortization
- 109.73
- Other Operating Expenses Total
- 604.51
- Total Operating Expense
- 2110.18
- Operating Income
- 496.78
- Net Income Before Taxes
- 562.33
- Net Income
- 453.76
- Diluted Normalized EPS
- 11.31
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Mankind Pharma Technical
Moving Average
SMA
- 5 Day2545.11
- 10 Day2478.6
- 20 Day2509.47
- 50 Day2401.99
- 100 Day2508.46
- 300 Day2493.75
Mankind Pharma Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Jio Financial Services
- 271.45
- -5.65
- -2.04
- 376
- 198.6
- 172456.03
- Hyundai Motor India
- 1884.1
- -11.5
- -0.61
- 1968.8
- 1542.95
- 153090.87
- Mankind Pharma
- 2538
- -22.2
- -0.87
- 3050
- 1910.1
- 104829.12
- Bajaj Housing Finance
- 123.85
- -2.4
- -1.9
- 188.45
- 103
- 103195.96
- Ntpc Green Energy
- 103
- -2.95
- -2.78
- 155.3
- 84.6
- 86791.19
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Jio Financial Services
- 106.84
- 1.43
- 1.11
- 98.65
- Hyundai Motor India
- 26.73
- 9.25
- -
- -
- Mankind Pharma
- 53.98
- 11.01
- -
- -
- Bajaj Housing Finance
- 45.1
- 5.17
- 13.08
- 21.32
- Ntpc Green Energy
- 255.92
- 14.16
- -
- -
Mankind Pharma Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 21-May-25
- Audited Results
- 23-Jan-25
- Quarterly Results
- 05-Nov-24
- Quarterly Results
- 31-Jul-24
- Quarterly Results
- 15-May-24
- Audited Results & Others
- 31-Jan-24
- Quarterly Results
- 31-Oct-23
- Quarterly Results
- 02-Aug-23
- Quarterly Results
- 30-May-23
- Audited Results
- Meeting Date
- Announced on
- Purpose
- 24-Dec-24
- 21-Nov-24
- POM
- 09-Aug-24
- 18-Jul-24
- AGM
- 22-Sept-23
- 02-Aug-23
- AGM



